FRANK MCCORMICK - 21 Jun 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
21 Jun 2024
Net transactions value
$0
Form type
4
Filing time
25 Jun 2024, 17:39:06 UTC
Previous filing
28 Dec 2023
Next filing
08 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBIO Common Stock 120,086 21 Jun 2024 Direct F1
holding BBIO Common Stock 979,979 21 Jun 2024 By The Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +26,014 $0.000000 26,014 21 Jun 2024 Common Stock 26,014 $27.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Excludes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F2 Includes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F3 One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.